Development of Metachronous Tumors after Endoscopic Resection for Gastric Neoplasm according to the Baseline Tumor Grade at a Health Checkup Center.
10.4166/kjg.2017.70.5.223
- Author:
Goh Eun CHUNG
1
;
Su Jin CHUNG
;
Jong In YANG
;
Eun Hyo JIN
;
Min Jung PARK
;
Sang Gyun KIM
;
Joo Sung KIM
Author Information
1. Department of Internal Medicine, Healthcare Research Institute, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea. medjsj7@hanmail.net
- Publication Type:Original Article
- Keywords:
Gastric neoplasm;
Recurrence;
Adenoma
- MeSH:
Adenoma;
Endoscopy;
Follow-Up Studies;
Humans;
Incidence;
Mass Screening;
Prognosis;
Recurrence;
Stomach Neoplasms*
- From:The Korean Journal of Gastroenterology
2017;70(5):223-231
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Endoscopic resection (ER) procedure has been performed widely to treat gastric neoplasms. Here, we compared the long-term prognosis based on the clinical features of three types of recurred gastric neoplasms after ER, including low-grade dysplasia (LGD), high-grade dysplasia (HGD), and early gastric carcinoma (EGC). METHODS: Between 2003 and 2014, subjects who were diagnosed with gastric neoplasm during screening endoscopy were included. The baseline clinicopathologic and tumor recurrence were analyzed. RESULTS: Of the 316 patients enrolled, 170 patients (53.8%) were categorized into the LGD group, 34 patients (10.8%) into the HGD group, and 112 patients (35.4%) into the EGC group. The median follow-up duration was 4.2 years. Among the total, 14 patients experienced a development of metachronous gastric cancer; 4 patients (2.3%) in the LGD group, 3 patients (8.3%) in the HGD group, and 7 patients (6.1%) in the EGC group. Metachronous gastric neoplasm had developed in 17 LGD patients (10.0%), 5 HGD patients (14.7%), and 14 EGC patients (12.5%). There was no significant difference in the incidence of metachronous gastric cancer and neoplasm among the three groups (p=0.15 and p=0.72, respectively). CONCLUSIONS: We identified that the incidence rates of gastric neoplasm and cancer after endoscopic treatment were not significantly different between the LGD, HGD, and EGC groups.
